Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cel-Sci Corp (AMEX:CVM) (was HIV) -- Ignore unavailable to you. Want to Upgrade?

To: George Bielski who wrote (2734)	10/26/1999 12:18:00 AM
From: Paul K	Read Replies (1) \| Respond to of 2836

A long, but fascinating article of a Cel-Sci vaccine competitor. Wouldn't Cel-Sci's pan-strain type vaccine get around the limitations of VaxGen's shotgun style formula? If so, then it would be seriously superior to AidsVax... newstrolls.com "...VaxGen no longer monitors what has happened to the people who received its product in the mid-1990s preliminary tests. Francis argues that it makes more sense to wait for the full-scale trial results. This apparent loss of data is surprising to some, because history warns of the pitfalls of not being thorough. In 1955, just one month after a near-hysterical press conference in Michigan launched polio vaccine, reports poured in to the CDC of hundreds of children going down with the disease, induced by the shots themselves. President Dwight Eisenhower said that, because of the "great pressure to bring this out", scientists may have "short-cut a little bit". AidsVax cannot give volunteers Aids, but there may be something even more terrifying than the anxiety that it might accelerate their disease if they are later infected with HIV...."